Patient-derived fibroblasts with known PD risk alleles (LRRK2, PRKN, or MAPT) or fibroblasts derived from patients with sporadic PD [51] were treated with RSL3 to induce time-dependent accumulation of oxidized lipids, a consequence of increased HETE production and LO activation. This evidence concerns the gene LRRK2 and Parkinson disease.